CriticalErgot alkaloid, 5-HT1B/1D and alpha-adrenoceptor agonist×Triptan, selective 5HT1B/1D receptor agonist
Updated · Methodology
Mechanism
Both drugs constrict blood vessels. Eletriptan is a selective agonist of vascular 5-HT1B and neuronal 5-HT1D serotonin receptors (eletriptan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and drugs of this class can cause coronary artery spasm (eletriptan label, US Food and Drug Administration, FDA). Dihydroergotamine binds to 5-HT1D receptors, and its main metabolite is as potent a venoconstrictor as the parent drug. Like other ergot alkaloids, dihydroergotamine can cause spasm of the coronary and other arteries (dihydroergotamine labels, FDA). Ergot drugs cause prolonged vasospasm, and their effects may add to those of eletriptan (eletriptan label, FDA). In clinical trials in which ergotamine with caffeine was given by mouth 1 and 2 hours after eletriptan, blood pressure rose only slightly, but the rises were additive, as expected from the pharmacology of both drugs (AEMPS). The documents give no data on the combination with dihydroergotamine itself.
Symptoms
Transient chest pain and tightness can occur after eletriptan and may be intense and spread to the throat (eletriptan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). They are usually not cardiac, but rare cases of myocardial infarction have been reported within a few hours of eletriptan, including in people without known coronary artery disease. Ventricular tachycardia and ventricular fibrillation have been reported within a few hours of drugs of this class, and myocardial infarction, life-threatening arrhythmias and transient myocardial ischaemia after dihydroergotamine (eletriptan and dihydroergotamine labels, US Food and Drug Administration, FDA). Spasm of other arteries shows as abdominal pain with bloody diarrhoea from bowel ischaemia and as Raynaud's syndrome, and with dihydroergotamine as muscle pain, numbness, coldness, pallor and bluish discolouration of the fingers and toes. In people with poor circulation, persistent vasospasm can lead to gangrene or death (eletriptan and dihydroergotamine labels, FDA). On rare occasions blood pressure has risen markedly after dihydroergotamine and after drugs of the eletriptan class, and hypertensive crisis with acute organ damage has been reported with the latter (dihydroergotamine and eletriptan labels, FDA).
Management
The combination is contraindicated. The Spanish eletriptan summary of product characteristics (SmPC) contraindicates ergotamine and its derivatives in the 24 hours before or after eletriptan, and its interactions section names dihydroergotamine among the ergot derivatives (eletriptan SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dihydroergotamine itself, however, is not in the Spanish medicines register. The US eletriptan label contraindicates dihydroergotamine by name if less than 24 hours separate the two drugs (eletriptan label, US Food and Drug Administration, FDA). The dihydroergotamine labels contraindicate dihydroergotamine in patients who have taken triptans in the previous 24 hours and name eletriptan among them (dihydroergotamine labels, FDA). Keep at least 24 hours between the two drugs, in either order (eletriptan SmPC, AEMPS, and label, FDA). If chest pain or tightness suggesting cardiac ischaemia appears after an eletriptan dose, withhold further doses and evaluate the patient (eletriptan SmPC, AEMPS). Stop eletriptan if arrhythmias occur (eletriptan label, FDA). Stop dihydroergotamine at once if signs of vasoconstriction appear (dihydroergotamine labels, FDA), and rule out vasospasm before the next eletriptan dose (eletriptan label, FDA). Monitor blood pressure during eletriptan treatment (eletriptan label, FDA). Eletriptan is contraindicated in severe or moderately severe hypertension and in untreated mild hypertension (AEMPS), and dihydroergotamine in uncontrolled hypertension (dihydroergotamine labels, FDA). Taking triptans and ergot drugs, alone or together, on 10 or more days a month can lead to medication overuse headache (eletriptan and dihydroergotamine labels, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Relpax (eletriptan hydrobromide) tablets – prescribing information (2024)– FDA label, Viatris Specialty, DailyMed setid 2a501dbd-3ea8-47e4-9fcb-07035b8c8c9e, version 4, 01/2024, sections 4, 5.7, 7.1, 7.2 and 7.3
- FDA: ATZUMI (dihydroergotamine) prescribing information (2026)– FDA, DailyMed setid 0982a44a-dc0c-75c0-e063-6394a90a6d6c, revisión 06/2026 (versión 3), secciones 4, 5.5, 5.6 y 7.2
- AEMPS: Ficha técnica: Eletriptán (nº registro 64124), sección 4.3 (2024)– AEMPS, CIMA, nº registro 64124 (Relpax 20 mg, Viatris), revisión 05/2024, secciones 4.3, 4.4 y 4.5
- FDA: TRUDHESA (dihydroergotamine) prescribing information (2026)– FDA, DailyMed setid b81397b0-910d-4eb4-8fee-a9a3c9d94d63, revisión 09/2026 (versión 7), secciones 4 y 7.2
- AEMPS: Ficha técnica: Eletriptán (nº registro 64124), sección 4.5 (2024)– AEMPS, CIMA, nº registro 64124 (Relpax 20 mg, Viatris), revisión 05/2024, secciones 4.4 y 4.5
- FDA: Dihydroergotamine mesylate nasal spray, Cipla (dihydroergotamine) prescribing information (2025)– FDA, DailyMed setid 1ecb2311-eee3-4230-a019-a3496308cff1 (Cipla USA), versión 10 (SPL 29.12.2025, texto revisado 05/2022), Contraindications